Preventing Covid with a vaccine is only one part of the solution – AXA IM

by | Nov 12, 2020

Share this article

Following the news earlier this week of the successful vaccine trial update from BioNTech and Pfizer, Linden Thomson, manager of the AXA Framlington Biotech fund,reminds us that there are other ways in which science is working hard to find ways to help humanity overcome the impact of Covid-19.  She comments: 

“A year ago COVID-19 was unheard of. Today it dominates our daily lives. Its impact is unparalleled, having caused unprecedented levels of disruption to the global economy and reportedly been the cause of more than 1.2 million deaths.

“The world has been pinning its hopes on a vaccine since the virus caused the start of a global lockdown earlier this year, and finally there has been some good news. The data this week from BioNTech and partner Pfizer announcing a 90% success rate of its trial vaccine has ignited a glimmer of hope. We are also expecting good news from Moderna and AstraZeneca before the end of the year, finally signalling the end of the pandemic.


“This is clearly very positive news, but we believe a mass rollout will take longer than expected, and there is a risk it could take until the second half of 2021. However, a vaccine isn’t the only solution. There are numerous biotechnology and pharmaceutical companies developing treatments which can reduce the severity of COVID-19 for those that become infected. Currently, there are more than 100 credible treatments being investigated. For example, Gilead Sciences antiviral treatment Remdesivir has been the first treatment to show positive clinical trial results and has been phased into some treatment of Covid in multiple countries.

“The spectrum of research into beating this pandemic can seem complex, but researchers, such as Gilead Sciences and Regeneron, are simply mining for solutions that can either prevent the infection from taking hold, or stop the collateral damage that the infection can induce when the immune system becomes overactive. We remain positive that the biotech sector will rise to the occasion to overcome the challenges presented by Covid-19.”

Share this article

Related articles

Winners of the Protection Guru Awards 2022 are announced

Winners of the Protection Guru Awards 2022 are announced

Protection Guru, has today announced the winners of Protection Guru Awards 2022. In this, their second year, the awards have been established to recognise the leading lights of the protection industry. The team at IFA Magazine extends our congratulations to all this...

Trending articles

IFA Talk logo

IFA Talk is our flagship podcast, designed to fit perfectly into your busy life, bringing the latest insight, analysis, news and interviews to you, wherever you are.

IFA Talk Podcast - listen to the latest episode